BR9808018A - Composições de lipìdio catiÈnico tendo como alvo células endoteliais angiogênicas - Google Patents

Composições de lipìdio catiÈnico tendo como alvo células endoteliais angiogênicas

Info

Publication number
BR9808018A
BR9808018A BR9808018-0A BR9808018A BR9808018A BR 9808018 A BR9808018 A BR 9808018A BR 9808018 A BR9808018 A BR 9808018A BR 9808018 A BR9808018 A BR 9808018A
Authority
BR
Brazil
Prior art keywords
angiogenic endothelial
endothelial cells
compositions
cationic lipid
targeting angiogenic
Prior art date
Application number
BR9808018-0A
Other languages
English (en)
Inventor
Donald M Macdonald
John Mclean
O Gavin Thurston
Peter Baluk
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9808018A publication Critical patent/BR9808018A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<B> COMPOSIçõES DE LIPìDIO CATIÈNICO TENDO COMO ALVO CéLULAS ENDOTELIAIS ANGIOGêNICAS <D>.Células endoteliais angiogênicas são seletivamente alvos com complexos de LIPìDIO/DNA ou lipossomas catiónicos contendo uma substância que afeta as células alvo inibindo ou promovendo seu crescimento. Um sítio de angiogênese pode ser localizado precisamente administrando lipossomas catiónicos contendo um rótulo detectável. Os complexos podem compreender construções de nucleotídeo que são compreendidas de promotores os quais são seletiva e exclusivamente ativados no meio ambiente de uma célula endotelial angiogênica.
BR9808018-0A 1997-03-12 1998-03-12 Composições de lipìdio catiÈnico tendo como alvo células endoteliais angiogênicas BR9808018A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/820,337 US5837283A (en) 1997-03-12 1997-03-12 Cationic lipid compositions targeting angiogenic endothelial cells
PCT/US1998/004891 WO1998040052A1 (en) 1997-03-12 1998-03-12 Cationic lipid compositions targeting angiogenic endothelial cells

Publications (1)

Publication Number Publication Date
BR9808018A true BR9808018A (pt) 2000-03-08

Family

ID=25230519

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808018-0A BR9808018A (pt) 1997-03-12 1998-03-12 Composições de lipìdio catiÈnico tendo como alvo células endoteliais angiogênicas

Country Status (13)

Country Link
US (7) US5837283A (pt)
EP (2) EP1014945B1 (pt)
JP (2) JP4463880B2 (pt)
KR (1) KR100530534B1 (pt)
AT (1) ATE362753T1 (pt)
AU (1) AU727946B2 (pt)
BR (1) BR9808018A (pt)
CA (1) CA2283327C (pt)
DE (1) DE69837807T2 (pt)
ES (1) ES2284201T3 (pt)
IL (2) IL131697A0 (pt)
NO (1) NO327487B1 (pt)
WO (1) WO1998040052A1 (pt)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6930094B1 (en) * 1997-05-09 2005-08-16 Merckle Gmbh Tissue factor for influencing blood vessel formation
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
US6130207A (en) * 1997-11-05 2000-10-10 South Alabama Medical Science Foundation Cell-specific molecule and method for importing DNA into a nucleus
US6082364A (en) * 1997-12-15 2000-07-04 Musculoskeletal Development Enterprises, Llc Pluripotential bone marrow cell line and methods of using the same
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
US6225293B1 (en) * 1998-09-02 2001-05-01 Isis Pharmaceuticals, Inc. Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
EP1829856A3 (en) 1998-11-12 2009-02-25 Invitrogen Corporation Transfection reagents
DK1059092T3 (da) * 1999-06-08 2006-03-27 Gentium Spa Anvendelse af komplekser af kationiske liposomer og polydeoxyribonukleotider som medikamenter
EP1210046A4 (en) * 1999-06-22 2007-05-02 Res Dev Foundation IMPROVED DRESSING THAT CAN ACCELERATE THE HEALING OF INJURIES
US6611833B1 (en) * 1999-06-23 2003-08-26 Tissueinformatics, Inc. Methods for profiling and classifying tissue using a database that includes indices representative of a tissue population
HK1046506B (en) * 1999-09-09 2006-08-25 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6716824B1 (en) 1999-10-22 2004-04-06 F. Charles Brunicardi Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
CA2389690A1 (en) * 1999-11-03 2001-05-10 Mbt Munich Biotechnology Gmbh Selective toxin expression in angiogenic endothelial cells
US6329348B1 (en) 1999-11-08 2001-12-11 Cornell Research Foundation, Inc. Method of inducing angiogenesis
US8029795B2 (en) * 1999-12-30 2011-10-04 Gwathmey, Inc. Targeted iron chelator delivery system
US6372722B1 (en) * 2000-01-19 2002-04-16 Genteric, Inc. Method for nucleic acid transfection of cells
AU6627201A (en) * 2000-05-03 2001-11-12 Mbt Munich Biotechnology Gmbh Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20020026945A1 (en) * 2000-07-24 2002-03-07 Gomer Charles J. Enhancement of photodynamic therapy by anti-angiogenic treatment
US20030082103A1 (en) * 2000-10-11 2003-05-01 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
WO2002064746A2 (en) * 2001-02-14 2002-08-22 Uab Research Foundation Combined transductional and transcriptional targeting system for improved gene delivery
EP1406698B1 (en) * 2001-03-02 2008-10-29 The Brigham and Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
US20020142304A1 (en) * 2001-03-09 2002-10-03 Anderson Daniel G. Uses and methods of making microarrays of polymeric biomaterials
US6936469B2 (en) 2001-03-22 2005-08-30 Chromos Molecular Systems Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030186390A1 (en) * 2001-03-22 2003-10-02 De Jong Gary Methods for delivering nucleic acid molecules into cells and assessment thereof
US7294511B2 (en) * 2001-03-22 2007-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
US20030166593A1 (en) * 2001-04-30 2003-09-04 Kenneth Chien Non-viral vesicle vector for cardiac specific gene delivery
US20050233990A1 (en) * 2001-08-29 2005-10-20 Yong-Serk Park Anti-cancer agents comprising disintegrin genes and the treating methods
AU2002362461A1 (en) * 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
AU2002350245A1 (en) * 2001-11-26 2003-06-10 Exelixis Inc. Mhyps as modifiers of branching morphogenesis and methods of use
US7488313B2 (en) * 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US7519418B2 (en) * 2002-04-30 2009-04-14 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
WO2003093469A2 (en) * 2002-05-01 2003-11-13 Chromos Molecular Systems, Inc. Methods for delivering nucleic acid molecules into cells and assessment thereof
EP1513538A4 (en) * 2002-06-14 2007-08-22 Mirus Bio Corp Novel methods for introducing polynucleotides into cells
US20030235565A1 (en) * 2002-06-18 2003-12-25 Cheung Ling Yuk Feed additives for shrimp culture
JP4975964B2 (ja) 2002-06-26 2012-07-11 メディゲーネ アクチエンゲゼルシャフト 脂肪親和性化合物から成る陽イオン性リポソームの製法
US20040034336A1 (en) * 2002-08-08 2004-02-19 Neal Scott Charged liposomes/micelles with encapsulted medical compounds
US20050026859A1 (en) * 2002-11-12 2005-02-03 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20080026077A1 (en) * 2002-11-12 2008-01-31 John Hilfinger Methods and compositions of gene delivery agents for systemic and local therapy
US20040197319A1 (en) * 2003-03-24 2004-10-07 Paul Harch Wound healing composition derived from low platelet concentration plasma
US7330851B2 (en) * 2003-08-18 2008-02-12 Eaglehawk, Limited Data security through dissembly of data elements or connections between elements
EP2286794B8 (en) 2003-10-15 2016-06-01 SynCore Biotechnology CO., LTD Use of cationic liposomes comprising paclitaxel
RU2007101074A (ru) * 2004-06-14 2008-07-20 Зозер Б. САЛАМА (DE) Фармацевтическая противораковая композиция пролина или его производных и противоопухолевого антитела
US20060134066A1 (en) * 2004-12-22 2006-06-22 Peyman Gholam A Localization of vectors and other agents
US9233094B2 (en) 2005-05-04 2016-01-12 Medigene Ag Method of administering a cationic liposomal preparation
EP2476756A1 (en) 2005-06-15 2012-07-18 Massachusetts Institute of Technology Amine-containing lipids and uses thereof
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
WO2007080902A1 (ja) * 2006-01-11 2007-07-19 Kyowa Hakko Kogyo Co., Ltd. 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤
WO2007089043A1 (ja) * 2006-02-03 2007-08-09 Takeda Pharmaceutical Company Limited リポソーム製剤
AU2007228984B2 (en) 2006-03-22 2012-05-03 Syncore Biotechnology Co., Ltd Treatment of triple receptor negative breast cancer
CA2691075C (en) 2007-06-15 2017-04-11 Daniela Gast Treatment of tumors using specific anti-l1 antibody
PT2222697E (pt) 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
MX2011004859A (es) 2008-11-07 2011-08-03 Massachusetts Inst Technology Lipidoides de aminoalcohol y usos de los mismos.
PL3338765T3 (pl) 2009-12-01 2019-06-28 Translate Bio, Inc. Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
PT2717893T (pt) 2011-06-08 2019-08-20 Translate Bio Inc Composições de nanopartículas lipídicas e métodos para transferência de arnm
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
EP2882706A1 (en) 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof
EP2968586B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Cftr mrna compositions and related methods and uses
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
MX2016005239A (es) 2013-10-22 2016-08-12 Shire Human Genetic Therapies Tratamiento con acido ribonucleico mensajero para la fenilcetonuria.
WO2015061467A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
CA2952824C (en) 2014-06-24 2023-02-21 Shire Human Genetic Therapies, Inc. Stereochemically enriched compositions for delivery of nucleic acids
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
AU2015327064B2 (en) 2014-09-30 2021-03-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to L1CAM (CD171)
SI3750545T1 (sl) 2014-11-17 2024-06-28 Cellectar Biosciences, Inc. Analogi fosfolipidnega etra kot nosilci zdravil, ki ciljajo na raka
WO2018023100A2 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Anti-idiotypic antibodies and related methods
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
SI3773544T1 (sl) 2018-04-10 2026-01-30 Cellectar Biosciences, Inc. Fosfolipid-flavaglin konjugati ter postopki njihove uporabe za ciljno zdravljenje raka
CN118421617A (zh) 2018-08-24 2024-08-02 川斯勒佰尔公司 用于纯化信使rna的方法
EP3883592A1 (en) 2018-11-21 2021-09-29 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr
WO2021055609A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
JP7631329B2 (ja) 2019-10-10 2025-02-18 セレクター・バイオサイエンシズ・インコーポレイテッド リン脂質－フラバグリン抱合体及び標的化されたがん治療のためのリン脂質－フラバグリン抱合体の使用方法
JP2023536326A (ja) 2020-08-05 2023-08-24 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460577A (en) * 1977-09-30 1984-07-17 Farmitalia Carlo Erba S.P.A. Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5264318A (en) * 1987-06-15 1993-11-23 Sanyo-Kokusaku Pulp Co., Ltd. Positive type photosensitive composition developable with water comprising a photocrosslinking agent, a water-soluble resin and an aqueous synthetic resin
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
JPH0395118A (ja) 1989-09-07 1991-04-19 Green Cross Corp:The プロスタグランジン含有脂肪小体製剤
EP0452457B1 (en) * 1989-11-03 1997-08-20 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
DE69114782T2 (de) * 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1993012240A1 (en) * 1991-12-17 1993-06-24 The Regents Of The University Of California Gene therapy for cystic fibrosis transmembrane conductance regulator activity (cftr)
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
DE69329073T2 (de) * 1992-03-23 2001-01-18 Georgetown University, Washington In liposomen verkapseltes taxol und verwendungsverfahren
WO1993024640A2 (en) * 1992-06-04 1993-12-09 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
EP0982302B1 (en) * 1993-06-11 2004-04-14 PHARMACIA &amp; UPJOHN COMPANY Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
DE69427251T2 (de) 1993-07-27 2001-10-31 Terumo K.K., Tokio/Tokyo Verabreichungssystem für Arzneistoffe
JP3570561B2 (ja) * 1993-07-27 2004-09-29 テルモ株式会社 血管内皮損傷部位を認識する担体
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5580898A (en) * 1994-05-24 1996-12-03 The Trustees Of The University Of Pennsylvania Method of stabilizing microtubules
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6071890A (en) * 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6126086A (en) * 1995-01-10 2000-10-03 Georgia Tech Research Corp. Oscillating capillary nebulizer with electrospray
DE19605279A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
AU2733697A (en) 1996-04-17 1997-11-07 Aronex Pharmaceuticals, Inc. Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
DE69736692T2 (de) * 1996-07-16 2007-06-14 Archibald James Mixson Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
EP0956051A1 (en) * 1996-09-12 1999-11-17 Genemedicine, Inc. Compositions and methods for pulmonary gene delivery
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
AU5646300A (en) 1999-02-10 2000-08-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of stimulating angiogenesis

Also Published As

Publication number Publication date
US7135192B2 (en) 2006-11-14
CA2283327C (en) 2008-07-15
ES2284201T3 (es) 2007-11-01
JP2007084565A (ja) 2007-04-05
US20020155102A1 (en) 2002-10-24
DE69837807D1 (de) 2007-07-05
KR100530534B1 (ko) 2005-11-22
JP4463880B2 (ja) 2010-05-19
AU727946B2 (en) 2001-01-04
NO327487B1 (no) 2009-07-13
US20040072795A1 (en) 2004-04-15
NO994413L (no) 1999-11-10
US20030077305A1 (en) 2003-04-24
US5837283A (en) 1998-11-17
EP1767192A3 (en) 2011-05-04
EP1014945B1 (en) 2007-05-23
AU6461398A (en) 1998-09-29
US6756055B2 (en) 2004-06-29
NO994413D0 (no) 1999-09-10
ATE362753T1 (de) 2007-06-15
US7094424B2 (en) 2006-08-22
US20020197306A1 (en) 2002-12-26
EP1014945A1 (en) 2000-07-05
US7494666B2 (en) 2009-02-24
EP1767192A2 (en) 2007-03-28
US6120799A (en) 2000-09-19
US20040192776A1 (en) 2004-09-30
WO1998040052A9 (en) 1999-09-02
IL131697A0 (en) 2001-03-19
EP1014945A4 (en) 2002-10-09
KR20000076182A (ko) 2000-12-26
JP2001509816A (ja) 2001-07-24
DE69837807T2 (de) 2007-10-11
IL171355A (en) 2010-12-30
WO1998040052A1 (en) 1998-09-17
CA2283327A1 (en) 1998-09-17

Similar Documents

Publication Publication Date Title
CA2283327A1 (en) Cationic lipid compositions targeting angiogenic endothelial cells
BR0013866A (pt) Distribuição de lipossomas catiÈnicos de taxanos aos vasos sanguineos angiogênicos
BR0112633A (pt) Método para substituir, translocar e empilhar dna em genomas eucarióticos
BR9803704A (pt) Quinazolina-4-ona como antagonistas do ampa.
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
TR199902731T2 (xx) Kimyasal bile�ikler.
BR0114199A (pt) Sequências de nucleotìdeos que medeiam a fertilidade masculina e métodos de uso das mesmas
BR0307253A (pt) Construtos de dna, sistema de expressão, métodos de supressão da expressão de um gene alvo numa célula, célula de planta transformada, planta transgênica e kit de supressão de expressão genética
BR112023016183A2 (pt) Conjugados de peptídeo de penetração celular e métodos de uso dos mesmos
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
ATE445417T1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
EP1721993A3 (en) Kits and methods for the detection of target nucleic acids with help of tag nucleic acids
BR9713160A (pt) Composição utilizável em alvejamento
DE69723057D1 (de) Nukleosid analogen
BR0302496A (pt) Composições farmacêuticas com atividade antibiótica
DE69708868D1 (de) Neue kationische cholesterin derivate mit zyklischen polaren gruppen
AR023582A1 (es) Polinucleotidos de npr1 de maiz y metodos de uso de los mismos
BR0008035A (pt) Composições isoladas de células de planta e seu uso na modificação de sinalização de célula de planta
AU3642701A (en) Hydrolytic enzyme substrates and assay method
Quest et al. Membrane association of flagellar creatine kinase in the sperm phosphocreatine shuttle.
BR0013121A (pt) Plantas transgênicas que expressam a toxina de photorhabdus
BR0014192A (pt) Conjugados de corantes e anticorpos contra estruturas-alvo da angiogênese, para representação intra-operativa da margem de tumores
AR011110A1 (es) Promotor del gen de endoglina humana, una construccion de acido nucleico que comprende al menos una secuencia promotora del gen de endoglina humana, unacelula que alberga dicha construccion de acido nucleico, y el uso de dicha construccion de acido nucleico para preparar un farmaco
PT1147419E (pt) Deteccao de celulas utilizando dominios especificos que se ligam as paredes celulares (cbd) de proteinas que se ligam as paredes celulares

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, COM BASE NOS ARTIGOS 8O, 10 ( VIII ), 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]